Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials
| Autor: | Rochelle Bagatell, Steven G. DuBois |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Adolescent MEDLINE Disease-Free Survival law.invention Neuroblastoma Young Adult Text mining Randomized controlled trial law Risk Factors Internal medicine medicine Humans High risk neuroblastoma Child Randomized Controlled Trials as Topic business.industry Editorials Infant Induction Chemotherapy Europe Child Preschool Female business |
| Zdroj: | J Clin Oncol |
| Popis: | Induction therapy is a critical component of the therapy of high-risk neuroblastoma. We aimed to assess if the Memorial Sloan Kettering Cancer Center (MSKCC) N5 induction regimen (MSKCC-N5) would improve metastatic complete response (mCR) rate and 3-year event-free survival (EFS) compared with rapid COJEC (rCOJEC; cisplatin [C], vincristine [O], carboplatin [J], etoposide [E], and cyclophosphamide [C]).Patients (age 1-20 years) with stage 4 neuroblastoma or stage 4/4s aged1 year withA total of six hundred thirty patients were randomly assigned to receive rCOJEC (n = 313) or MSKCC-N5 (n = 317). Median age at diagnosis was 3.2 years (range, 1 month to 20 years), and 16 were younger than 1 year of age withNo difference in outcome was observed between rCOJEC and MSKCC-N5; however, acute toxicity was less with rCOJEC, and therefore rCOJEC is the preferred induction regimen for International Society of Pediatric Oncology European Neuroblastoma Group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|